Chronic hypoxic exposure induces changes in the structure of pulmonary arteries, as well as
in the biochemical and functional phenotypes of each of the vascular cell types, from the …

The secondary role of pathology in the present clinical management of pulmonary
hypertension (PH) reflects to some extent the limitations of the current understanding of the …

Rationale: Chronic hypoxia induces pulmonary vascular remodeling, pulmonary
hypertension, and right ventricular hypertrophy. At present, little is known about mechanisms …

In the lungs, parenchymal and vascular remodelling share pathomechanisms that may
explain the relatively high prevalence (30–40%) of pulmonary hypertension (PH) in …

Idiopathic pulmonary fibrosis (IPF) is a disabling disease of the lung parenchyma,
characterized by progressive accumulation of scar tissue and myofibroblast activation after …

Idiopathic pulmonary fibrosis (IPF) can lead to the development of secondary pulmonary
hypertension (PH) and ultimately death. Despite this known association, the precise …

Interstitial lung diseases (ILDs), a broad heterogeneous group of parenchymal lung
disorders, can be classified into those with known and unknown causes. The definitions and …

Group 3 pulmonary hypertension (PH) is a common complication of chronic lung disease
(CLD), including chronic obstructive pulmonary disease (COPD), interstitial lung disease …

The lung is one of the most common extra-muscular targets in idiopathic inflammatory
myopathies (IIM) and interstitial lung disease (ILD) is a prevalent and often devastating …

The COVID-19 pandemic has had a significant impact on the health and economy of the
global population. Even after recovery from the disease, post-COVID-19 symptoms, such as …